



Office_NNP of_IN the_DT General_NNP Counsel_NNP
B-_NNP 274333_CD
September_NNP 12_CD ,_, 1996_CD
The_DT Honorable_NNP Nancy_NNP Landon_NNP Kassebaum_NNP Chairman_NNP The_DT Honorable_NNP
Edward_NNP M_NNP ._. Kennedy_NNP Ranking_NNP Minority_NNP Member_NNP Committee_NNP on_IN Labor_NNP and_CC
Human_NNP Resources_NNPS United_NNP States_NNPS Senate_NNP
The_DT Honorable_NNP Thomas_NNP J_NNP ._. Bliley_NNP ,_, Jr_NNP ._. Chairman_NNP The_DT Honorable_NNP John_NNP
D_NNP ._. Dingell_NNP Ranking_NNP Minority_NNP Member_NNP Committee_NNP on_IN Commerce_NNP House_NNP of_IN
Representatives_NNPS
Subject_NNP :_: Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP
Administration_NNP :_: Regulations_NNPS Restricting_NNP the_DT Sale_NN and_CC Distribution_NN
of_IN Cigarettes_NNP and_CC Smokeless_NNP Tobacco_NNP to_TO Protect_NNP Children_NNP and_CC
Adolescents_NNP
Pursuant_NNP to_TO section_NN 801_CD (_( a_DT )_) (_( 2_LS )_) (_( A_DT )_) of_IN title_NN 5_CD ,_, United_NNP States_NNPS Code_NNP ,_,
this_DT is_VBZ our_PRP$ report_NN on_IN a_DT major_JJ rule_NN promulgated_VBD by_IN Department_NNP of_IN
Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP Administration_NNP ,_, entitled_VBN
"_'' Regulations_NNPS Restricting_NNP the_DT Sale_NN and_CC Distribution_NN of_IN Cigarettes_NNP
and_CC Smokeless_NNP Tobacco_NNP to_TO Protect_NNP Children_NNP and_CC Adolescents_NNP "_'' (_( RIN_NNP :_:
0910_CD -_: AA_NN 48_CD )_) ._. We_PRP received_VBD the_DT rule_NN on_IN August_NNP 26_CD ,_, 1996_CD ._. It_PRP was_VBD
published_VBN in_IN the_DT Federal_NNP Register_NNP as_IN a_DT final_JJ rule_NN on_IN August_NNP 28_CD ,_,
1996_CD ._. 61_CD Fed_NNP ._. Reg_NNP ._. 44395_CD ._.
The_DT rule_NN prohibits_VBZ the_DT sale_NN of_IN nicotine-containing_JJ cigarettes_NNS
and_CC smokeless_JJ tobacco_NN to_TO individuals_NNS under_IN the_DT age_NN of_IN 18_CD ;_: requires_VBZ
manufacturers_NNS ,_, distributors_NNS ,_, and_CC retailers_NNS to_TO comply_VB with_IN various_JJ
conditions_NNS regarding_VBG the_DT sale_NN and_CC distribution_NN of_IN these_DT products_NNS ;_:
requires_VBZ retailers_NNS to_TO verify_VB a_DT purchaser_NN 's_POS age_NN by_IN photographic_JJ
identification_NN ;_: prohibits_VBZ all_DT free_JJ samples_NNS ;_: limits_VBZ the_DT distribution_NN
of_IN these_DT products_NNS through_IN vending_VBG machines_NNS and_CC self-service_JJ
displays_NNS by_IN permitting_VBG such_JJ methods_NNS of_IN sale_NN only_RB in_IN facilities_NNS
where_WRB access_NN by_IN individuals_NNS under_IN 18_CD is_VBZ prohibited_VBN ;_: limits_VBZ the_DT
advertising_NN and_CC labeling_VBG to_TO which_WDT children_NNS and_CC adolescents_NNS are_VBP
exposed_VBN ;_: prohibits_VBZ promotional_JJ ,_, non-tobacco_JJ items_NNS such_JJ as_IN hats_NNS and_CC
tee_NN shirts_NNS ;_: prohibits_VBZ sponsorship_NN of_IN
GAO_NNP /_NN OGC-_NNP 96_CD -_: 38_CD
sporting_VBG and_CC other_JJ events_NNS ,_, teams_NNS and_CC entries_NNS in_IN the_DT brand_NN name_NN
of_IN tobacco_NN products_NNS ;_: and_CC requires_VBZ manufacturers_NNS to_TO provide_VB intended_VBN
use_NN information_NN on_IN all_DT cigarette_NN and_CC smokeless_JJ tobacco_NN product_NN
labels_NNS and_CC in_IN cigarette_NN advertising_NN ._.
The_DT rule_NN is_VBZ predicated_VBN on_IN the_DT Food_NNP and_CC Drug_NNP Administration_NNP 's_POS
assertion_NN of_IN jurisdiction_NN under_IN the_DT Federal_NNP Food_NNP ,_, Drug_NNP and_CC Cosmetic_NNP
Act_NNP over_IN cigarettes_NNS and_CC smokeless_JJ tobacco_NN as_IN delivery_NN devices_NNS for_IN
nicotine_NN ._. The_DT lengthy_JJ jurisdictional_JJ determination_NN was_VBD published_VBN in_IN
the_DT Federal_NNP Register_NNP on_IN August_NNP 28_CD ,_, 1996_CD ,_, as_IN an_DT annex_NN to_TO the_DT final_JJ
rule_NN ._.
The_DT rule_NN will_MD become_VB effective_JJ 1_CD year_NN from_IN the_DT date_NN of_IN
publication_NN in_IN the_DT Federal_NNP Register_NNP except_IN that_IN the_DT prohibition_NN
regarding_VBG sale_NN to_TO any_DT person_NN younger_JJR than_IN 18_CD years_NNS of_IN age_NN and_CC the_DT
requirement_NN for_IN photographic_JJ identification_NN to_TO verify_VB the_DT age_NN of_IN
purchasers_NNS will_MD become_VB effective_JJ 6_CD months_NNS after_IN publication_NN ._. The_DT
restriction_NN on_IN event_NN sponsorship_NN and_CC manufacturers_NNS '_POS compliance_NN with_IN
existing_VBG device_NN registration_NN and_CC listing_NN requirements_NNS and_CC good_JJ
manufacturing_VBG practice_NN requirements_NNS will_MD become_VB effective_JJ 2_CD years_NNS
from_IN publication_NN ._.
Enclosed_NNP is_VBZ our_PRP$ assessment_NN of_IN the_DT Food_NNP and_CC Drug_NNP Administration_NNP 's_POS
compliance_NN with_IN the_DT procedural_JJ steps_NNS required_VBN by_IN sections_NNS
801_CD (_( a_DT )_) (_( 1_LS )_) (_( B_NNP )_) (_( i_NNP )_) through_IN (_( iv_NN )_) of_IN title_NN 5_CD with_IN respect_NN to_TO the_DT rule_NN ._.
Our_PRP$ review_NN indicates_VBZ that_IN the_DT Administration_NNP complied_VBD with_IN the_DT
applicable_JJ requirements_NNS ._.
If_IN you_PRP have_VBP any_DT questions_NNS about_IN this_DT report_NN ,_, please_VB contact_NN
James_NNP W_NNP ._. Vickers_NNP ,_, Senior_NNP Attorney_NNP ,_, at_IN (_( 202_CD )_) 512_CD -_: 8210_CD ._. The_DT official_NN
responsible_JJ for_IN GAO_NNP evaluation_NN work_NN relating_VBG to_TO the_DT Department_NNP of_IN
Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP Administration_NNP is_VBZ Sarah_NNP F_NNP ._.
Jaggar_NNP ,_, Director_NNP ,_, Health_NNP Services_NNPS ,_, Quality_NNP and_CC Public_NNP Health_NNP
Issues_NNPS ._. Ms_NNP ._. Jaggar_NNP can_MD be_VB reached_VBN at_IN (_( 202_CD )_) 512_CD -_: 7119_CD ._.
Robert_NNP P_NN ._. Murphy_NNP General_NNP Counsel_NNP
Enclosure_NNP
cc_NN :_: The_DT Honorable_NNP Donna_NNP E_NNP ._. Shalala_NNP The_DT Secretary_NNP of_IN Health_NNP and_CC
Human_NNP Services_NNPS
Page_NNP 2_CD GAO_NNP /_NN OGC-_NNP 96_CD -_: 38_CD
ENCLOSURE_NNP
ANALYSIS_NNP UNDER_IN 5_CD U_NNP ._. S_NNP ._. C_NNP ._. ยง_NN ยง_NN 801_CD (_( a_DT )_) (_( 1_LS )_) (_( B_NNP )_) (_( i_NNP )_) -_: (_( iv_NN )_) OF_IN A_DT MAJOR_NNP RULE_NNP
ISSUED_NNP BY_NNP THE_DT DEPARTMENT_NNP OF_IN HEALTH_NN AND_CC HUMAN_NNP SERVICES_NNS ,_, FOOD_NN AND_CC
DRUG_NNP ADMINISTRATION_NNP ENTITLED_NNP "_'' REGULATIONS_NNS RESTRICTING_NNP THE_DT SALE_NNP AND_CC
DISTRIBUTION_NNP OF_IN CIGARETTES_NNP AND_CC SMOKELESS_NNP TOBACCO_NNP TO_TO PROTECT_NNP
CHILDREN_NNS AND_CC ADOLESCENTS_NNP "_'' (_( RIN_NNP :_: 0910_CD -_: AA_NN 48_CD )_)
(_( i_NNP )_) Cost-benefit_NNP analysis_NN
An_DT analysis_NN of_IN the_DT costs_NNS and_CC benefits_NNS of_IN the_DT rule_NN was_VBD conducted_VBN
by_IN the_DT Food_NNP and_CC Drug_NNP Administration_NNP (_( FDA_NNP )_) and_CC published_VBN in_IN the_DT
notice_NN of_IN proposed_VBN rulemaking_VBG on_IN August_NNP 11_CD ,_, 1995_CD ,_, and_CC is_VBZ contained_VBN
in_IN the_DT preamble_NN to_TO the_DT final_JJ rule_NN ._. The_DT analysis_NN in_IN the_DT final_JJ rule_NN
has_VBZ been_VBN revised_VBN based_VBN on_IN comments_VBZ the_DT FDA_NNP received_VBD and_CC now_RB also_RB
considers_VBZ the_DT costs_NNS and_CC benefits_NNS associated_VBN with_IN a_DT rule_NN issued_VBN by_IN
the_DT Substance_NNP Abuse_NNP and_CC Mental_NNP Health_NNP Services_NNPS Administration_NNP
(_( SAMHSA_NNP )_) on_IN January_NNP 19_CD ,_, 1996_CD ,_, governing_VBG a_DT program_NN of_IN State-operated_NNP
enforcement_NN activities_NNS to_TO restrict_VB the_DT sale_NN or_CC distribution_NN of_IN
tobacco_NN products_NNS to_TO individuals_NNS under_IN the_DT age_NN of_IN 18_CD ._. FDA_NNP considers_VBZ
the_DT two_CD rules_NNS complementary_JJ and_CC cannot_NN separately_RB quantify_VB the_DT
benefits_NNS of_IN the_DT two_CD programs_NNS and_CC since_IN both_DT rules_NNS work_VBP collectively_RB
to_TO reduce_VB youth_NN access_NN to_TO tobacco_NN products_NNS ,_, the_DT costs_NNS attributable_JJ
to_TO the_DT SAMHSA_NNP program_NN are_VBP included_VBN in_IN the_DT analysis_NN ._.
The_DT analysis_NN based_VBD its_PRP$ benefits_NNS on_IN achieving_VBG the_DT "_'' Healthy_JJ People_NNS
2000_CD ,_, "_'' a_DT Department_NNP program_NN ,_, goal_NN of_IN reducing_VBG underage_NN tobacco_NN use_NN
by_IN one-half_JJ in_IN order_NN to_TO prevent_VB over_IN 60_CD ,_, 000_CD early_JJ deaths_NNS ._. The_DT
analysis_NN places_VBZ a_DT monetary_JJ value_NN of_IN these_DT health_NN benefits_NNS (_( at_IN a_DT 3_CD
percent_NN discount_NN rate_NN )_) at_IN an_DT estimated_VBN $_$ 28_CD to_TO $_$ 43_CD billion_CD per_IN year_NN ,_,
including_VBG $_$ 2_CD ._. 6_CD billion_CD in_IN medical_JJ cost_NN savings_NNS ,_, $_$ 900_CD million_CD in_IN
productivity_NN gains_NNS from_IN reduced_VBN morbidity_NN and_CC $_$ 24_CD ._. 6_CD to_TO $_$ 39_CD ._. 7_CD
billion_CD per_IN year_NN in_IN willingness-to-pay_JJ values_NNS for_IN averting_VBG
premature_JJ fatalities_NNS ._. The_DT analysis_NN states_NNS that_IN if_IN the_DT 50_CD percent_NN
reduction_NN in_IN underage_NN tobacco_NN use_NN is_VBZ not_RB reached_VBN and_CC only_RB 5_CD percent_NN
of_IN the_DT 1_CD million_CD adolescents_NNS who_WP become_VBP new_JJ smokers_NNS are_VBP deterred_VBD ,_,
the_DT annual_JJ benefits_NNS would_MD be_VB $_$ 2_CD ._. 8_CD to_TO $_$ 4_CD ._. 3_LS billion_CD per_IN year_NN ._.
FDA_NNP estimates_VBZ the_DT overall_JJ compliance_NN costs_NNS of_IN the_DT rule_NN to_TO be_VB
from_IN $_$ 174_CD million_CD to_TO $_$ 187_CD million_CD in_IN one-time_JJ costs_NNS and_CC $_$ 149_CD
million_CD to_TO $_$ 185_CD million_CD in_IN annual_JJ operating_NN costs_NNS ._. These_DT costs_NNS will_MD
be_VB borne_VBN by_IN manufacturers_NNS (_( $_$ 78_CD to_TO $_$ 91_CD million_CD in_IN one-time_JJ costs_NNS and_CC
$_$ 2_CD million_CD in_IN annual_JJ costs_NNS )_) ,_, retail_JJ establishments_NNS (_( $_$ 96_CD million_CD in_IN
one-time_JJ costs_NNS and_CC $_$ 78_CD million_CD in_IN annual_JJ costs_NNS )_) ,_, FDA_NNP (_( $_$ 3_CD to_TO $_$ 5_CD
million_CD in_IN enforcement_NN costs_NNS per_IN year_NN )_) and_CC State_NNP governments_NNS (_( $_$ 25_CD
to_TO $_$ 50_CD million_CD per_IN year_NN in_IN administering_VBG various_JJ SAMHSA_NNP enforcement_NN
programs_NNS )_) ._.
GAO_NNP /_NN OGC-_NNP 96_CD -_: 38_CD
FDA_NNP recognizes_VBZ that_IN it_PRP could_MD not_RB quantify_VB every_DT regulatory_JJ cost_NN
because_IN of_IN significant_JJ distributional_NN and_CC transitional_JJ effects_NNS of_IN
the_DT rule_NN ._. For_IN example_NN ,_, lost_VBD sales_NNS experienced_VBN by_IN suppliers_NNS of_IN
advertising_NN were_VBD considered_VBN distributional_NN impacts_NNS because_IN the_DT
dollars_NNS not_RB spent_VBD on_IN advertising_NN are_VBP not_RB lost_VBN to_TO the_DT economy_NN but_CC
will_MD be_VB spent_VBN on_IN other_JJ goods_NNS and_CC services_NNS ._. Also_RB ,_, if_IN State_NNP and_CC
Federal_NNP excise_NN taxes_NNS remain_VBP at_IN the_DT current_JJ levels_NNS ,_, tax_NN revenues_NNS
will_MD decrease_VB over_IN time_NN because_IN of_IN decreased_VBD sales_NNS ._.
In_IN conclusion_NN ,_, the_DT analysis_NN finds_VBZ that_IN while_IN compliance_NN with_IN the_DT
rule_NN will_MD bring_VB significant_JJ health_NN benefits_NNS to_TO the_DT population_NN and_CC
also_RB exact_JJ long-term_JJ revenue_NN losses_NNS on_IN the_DT tobacco_NN industry_NN and_CC
short-term_JJ costs_NNS on_IN various_JJ affiliated_VBN industry_NN sectors_NNS ,_, the_DT
benefits_NNS of_IN the_DT rule_NN will_MD greatly_RB exceed_VB the_DT compliance_NN costs_NNS on_IN
the_DT United_NNP States_NNPS economy_NN ._.
(_( ii_NN )_) Agency_NNP actions_NNS relevant_JJ to_TO the_DT Regulatory_NNP Flexibility_NNP Act_NNP ,_,
5_CD U_NNP ._. S_NNP ._. C_NNP ._. ยง_NN ยง_NN 603_CD -_: 605_CD ,_, 607_CD and_CC 609_CD
The_DT FDA_NNP has_VBZ concluded_VBN that_IN the_DT rule_NN will_MD have_VB a_DT significant_JJ
economic_JJ impact_NN on_IN a_DT substantial_JJ number_NN of_IN small_JJ entities_NNS and_CC an_DT
initial_JJ regulatory_JJ flexibility_NN analysis_NN and_CC final_JJ regulatory_JJ
flexibility_NN analysis_NN have_VBP been_VBN prepared_VBN and_CC included_VBN in_IN the_DT notice_NN
of_IN proposed_VBN rulemaking_VBG and_CC the_DT final_JJ rule_NN notice_NN ,_, respectively_RB ,_, as_IN
required_VBN by_IN sections_NNS 603_CD and_CC 604_CD ._. The_DT analyses_NNS comply_VB with_IN the_DT
informational_JJ requirements_NNS of_IN the_DT sections_NNS including_VBG the_DT classes_NNS of_IN
small_JJ entities_NNS subject_JJ to_TO the_DT rule_NN and_CC alternatives_NNS considered_VBN to_TO
reduce_VB the_DT burden_NN on_IN the_DT small_JJ entities_NNS ._.
The_DT final_JJ analysis_NN discusses_NNS the_DT FDA_NNP 's_POS decision_NN not_RB to_TO exempt_VB
small_JJ entities_NNS from_IN the_DT rule_NN because_IN an_DT exemption_NN for_IN small_JJ
retailers_NNS would_MD shift_VB underage_NN sales_NNS to_TO those_DT locations_NNS ,_, lessening_VBG
or_CC eliminating_VBG the_DT effectiveness_NN and_CC benefits_NNS of_IN the_DT access_NN
restrictions_NNS ._. However_RB ,_, a_DT total_JJ ban_NN on_IN vending_VBG machines_NNS and_CC direct_JJ
mail_NN order_NN sales_NNS have_VBP been_VBN deleted_VBN from_IN the_DT final_JJ rule_NN because_IN of_IN
their_PRP$ impact_NN on_IN small_JJ entities_NNS ._.
The_DT analyses_NNS use_VBP both_DT quantifiable_JJ and_CC general_JJ descriptions_NNS of_IN
the_DT effects_NNS of_IN the_DT rule_NN on_IN small_JJ entities_NNS as_IN required_VBN by_IN section_NN
607_CD and_CC numerous_JJ small_JJ entities_NNS participated_VBD in_IN the_DT rulemaking_VBG as_IN
required_VBN by_IN section_NN 609_CD by_IN submitting_VBG comments_NNS on_IN the_DT proposed_VBN
regulation_NN following_VBG the_DT inclusion_NN in_IN the_DT notice_NN of_IN proposed_VBN
rulemaking_VBG of_IN the_DT initial_JJ regulatory_JJ flexibility_NN analysis_NN which_WDT
discussed_VBD the_DT economic_JJ impact_NN on_IN small_JJ entities_NNS ._.
Page_NNP 2_CD GAO_NNP /_NN OGC-_NNP 96_CD -_: 38_CD
(_( iii_NN )_) Agency_NNP actions_NNS relevant_JJ to_TO sections_NNS 202_CD -_: 205_CD of_IN the_DT
Unfunded_NNP Mandates_NNP Reform_NNP Act_NNP of_IN 1995_CD ,_, 2_CD U_NNP ._. S_NNP ._. C_NNP ._. ยง_NN ยง_NN 1532_CD -_: 1535_CD
Based_VBN on_IN the_DT cost-benefit_JJ analysis_NN performed_VBN by_IN FDA_NNP ,_, the_DT rule_NN
will_MD impose_VB an_DT unfunded_JJ mandate_NN on_IN the_DT private_JJ sector_NN of_IN over_IN $_$ 100_CD
million_CD annually_RB and_CC therefore_RB the_DT rule_NN is_VBZ subject_JJ to_TO the_DT
requirements_NNS of_IN the_DT Act_NNP ._.
As_IN required_VBN by_IN section_NN 205_CD ,_, FDA_NNP considered_VBN regulatory_JJ
alternatives_NNS to_TO the_DT requirements_NNS of_IN the_DT rule_NN but_CC determined_VBN that_IN
the_DT provisions_NNS of_IN the_DT final_JJ rule_NN constituted_VBD the_DT most_RBS
cost-effective_JJ and_CC least_JJS burdensome_JJ alternative_NN that_WDT would_MD meet_VB the_DT
objective_NN of_IN the_DT rule_NN ._.
The_DT FDA_NNP rejected_VBD the_DT regulatory_JJ alternative_NN of_IN a_DT total_JJ ban_NN on_IN
all_DT tobacco_NN advertising_NN ._. Also_RB ,_, a_DT more_RBR prescriptive_JJ requirement_NN for_IN
manufacturers_NNS to_TO monitor_VB the_DT sales_NNS and_CC distribution_NN of_IN retail_JJ
establishments_NNS was_VBD not_RB imposed_VBN because_IN it_PRP would_MD have_VB imposed_VBN an_DT
additional_JJ cost_NN of_IN $_$ 85_CD million_CD per_IN year_NN ._. Finally_RB ,_, a_DT requirement_NN to_TO
include_VB package_NN inserts_NNS containing_VBG educational_JJ information_NN in_IN
cigarette_NN and_CC smokeless_JJ tobacco_NN was_VBD not_RB chosen_VBN because_IN the_DT FDA_NNP was_VBD
not_RB certain_JJ the_DT benefits_NNS would_MD justify_VB the_DT compliance_NN costs_NNS ._.
Section_NN 204_CD requires_VBZ that_IN State_NNP ,_, local_NN and_CC tribal_NN governments_NNS
have_VBP an_DT opportunity_NN for_IN input_NN and_CC numerous_JJ comments_NNS were_VBD received_VBN
from_IN State_NNP and_CC local_JJ governments_NNS ,_, health_NN departments_NNS ,_, substance_NN
abuse_NN programs_NNS and_CC law_NN enforcement_NN agencies_NNS ._. These_DT comments_NNS were_VBD
reviewed_VBN and_CC considered_VBN as_IN discussed_VBN in_IN the_DT preamble_NN to_TO the_DT final_JJ
rule_NN ._.
(_( iv_NN )_) Other_JJ relevant_JJ information_NN or_CC requirements_NNS under_IN Acts_NNP and_CC
Executive_NNP orders_NNS
Administrative_NNP Procedure_NNP Act_NNP ,_, 5_CD U_NNP ._. S_NNP ._. C_NNP ._. ยง_NN ยง_NN 551_CD et_CC seq_NN ._.
The_DT FDA_NNP promulgated_VBD the_DT rule_NN under_IN the_DT notice_NN and_CC comment_VB
procedures_NNS of_IN 5_CD U_NNP ._. S_NNP ._. C_NNP ._. ยง_NN 553_CD and_CC its_PRP$ own_JJ agency_NN regulation_NN
regarding_VBG the_DT promulgation_NN of_IN regulations_NNS found_VBD at_IN section_NN 10_CD ._. 40_CD of_IN
Title_NNP 21_CD of_IN the_DT Code_NNP of_IN Federal_NNP Regulations_NNPS ._.
On_IN August_NNP 11_CD ,_, 1995_CD ,_, the_DT proposed_VBN rule_NN was_VBD published_VBN in_IN the_DT
Federal_NNP Register_NNP (_( 60_CD Fed_NNP ._. Reg_NNP ._. 41314_CD )_) and_CC in_IN the_DT same_JJ issue_NN ,_, a_DT
document_NN entitled_VBN "_'' Analysis_NNP Regarding_VBG The_DT Food_NNP And_CC Drug_NNP
Administration_NNP 's_POS Jurisdiction_NNP Over_IN Nicotine-_NNP Containing_NNP Cigarettes_NNP
And_CC Smokeless_NNP Tobacco_NNP Products_NNPS "_'' was_VBD published_VBN and_CC comments_NNS were_VBD
requested_VBN ._. 60_CD Fed_NNP ._. Reg_NNP ._. 41453_CD ._. The_DT comment_NN period_NN ,_, following_VBG an_DT
extension_NN ,_, remained_VBD open_JJ for_IN 144_CD days_NNS ._. In_IN the_DT months_NNS that_WDT followed_VBD
the_DT publication_NN of_IN the_DT proposed_VBN rule_NN and_CC during_IN the_DT comment_NN period_NN ,_,
the_DT FDA_NNP made_VBD available_JJ to_TO the_DT public_NN over_IN 200_CD ,_, 000_CD pages_NNS of_IN
documents_NNS which_WDT were_VBD cited_VBN by_IN the_DT agency_NN or_CC considered_VBN in_IN the_DT
promulgation_NN of_IN the_DT rule_NN ._.
Page_NNP 3_CD GAO_NNP /_NN OGC-_NNP 96_CD -_: 38_CD
The_DT FDA_NNP received_VBD over_IN 700_CD ,_, 000_CD comments_NNS in_IN response_NN to_TO the_DT
proposed_VBN rule_NN ._. While_IN the_DT FDA_NNP reports_NNS many_JJ of_IN the_DT comments_NNS were_VBD form_NN
letters_NNS ,_, there_EX were_VBD over_IN 95_CD ,_, 000_CD distinct_JJ or_CC unique_JJ comments_NNS filed_VBN
with_IN the_DT FDA_NNP ._.
The_DT preamble_NN to_TO the_DT final_JJ rule_NN discusses_NNS many_JJ of_IN the_DT comments_NNS
received_VBD and_CC the_DT action_NN taken_VBN by_IN the_DT agency_NN in_IN response_NN or_CC why_WRB the_DT
comments_NNS did_VBD not_RB change_VB the_DT agency_NN 's_POS position_NN ._.
Paperwork_NNP Reduction_NNP Act_NNP ,_, 44_CD U_NNP ._. S_NNP ._. C_NNP ._. ยง_NN ยง_NN 3501_CD -_: 3520_CD
The_DT proposed_VBN rule_NN contained_VBD information_NN collections_NNS which_WDT would_MD
have_VB required_VBN the_DT manufacturers_NNS and_CC retailers_NNS of_IN cigarettes_NNS and_CC
smokeless_JJ tobacco_NN to_TO use_VB established_VBD names_NNS for_IN cigarettes_NNS and_CC
smokeless_JJ tobacco_NN products_NNS ,_, establish_VB and_CC maintain_VB educational_JJ
programs_NNS ,_, observe_VBP certain_JJ formats_NNS and_CC content_NN requirements_NNS for_IN
labeling_VBG and_CC advertising_VBG and_CC the_DT submission_NN of_IN labels_NNS ,_, labeling_VBG and_CC
advertising_VBG to_TO the_DT FDA_NNP ._. The_DT FDA_NNP solicited_VBD comments_NNS on_IN the_DT above_JJ
information_NN collections_NNS including_VBG among_IN other_JJ information_NN ,_, the_DT
necessity_NN of_IN the_DT collection_NN ,_, the_DT accuracy_NN of_IN the_DT estimated_VBN burden_NN
and_CC ways_NNS to_TO enhance_VB the_DT information_NN collection_NN ._.
Following_VBG the_DT receipt_NN and_CC evaluation_NN of_IN the_DT comments_NNS ,_, the_DT FDA_NNP
has_VBZ revised_VBN certain_JJ burden_NN estimates_NNS and_CC has_VBZ deleted_VBN the_DT
requirement_NN for_IN the_DT submission_NN of_IN labeling_VBG to_TO the_DT FDA_NNP and_CC the_DT
establishment_NN of_IN educational_JJ programs_NNS ._.
The_DT information_NN collections_NNS in_IN the_DT proposed_VBN rule_NN were_VBD approved_VBN
by_IN the_DT Office_NNP of_IN Management_NNP and_CC Budget_NNP under_IN OMB_NNP No_UH ._. 0910_CD -_: 0312_CD ._.
Because_IN of_IN the_DT above_JJ noted_VBD changes_NNS to_TO the_DT collections_NNS ,_, FDA_NNP has_VBZ
resubmitted_JJ the_DT matter_NN to_TO OMB_NNP for_IN review_NN and_CC approval_NN and_CC prior_RB to_TO
the_DT effective_JJ date_NN of_IN the_DT rule_NN ,_, FDA_NNP will_MD publish_VB a_DT notice_NN in_IN the_DT
Federal_NNP Register_NNP of_IN OMB_NNP 's_POS action_NN on_IN the_DT provisions_NNS ._.
Statutory_NNP authorization_NN for_IN the_DT rule_NN
The_DT FDA_NNP has_VBZ cited_VBN sections_NNS 502_CD ,_, 510_CD ,_, 518_CD ,_, 519_CD ,_, 520_CD ,_, 701_CD ,_, 704_CD and_CC
903_CD of_IN the_DT Federal_NNP Food_NNP ,_, Drug_NNP and_CC Cosmetic_NNP Act_NNP (_( 21_CD U_NNP ._. S_NNP ._. C_NNP ._. ยง_NN ยง_NN 352_CD ,_,
360_CD ,_, 360_CD h_NN ,_, 360_CD i_NNP ,_, 360_CD j_NN ,_, 371_CD ,_, 374_CD and_CC 393_CD )_) as_IN authority_NN for_IN the_DT rule_NN
and_CC in_IN particular_JJ ,_, the_DT device_NN provisions_NNS of_IN the_DT Act_NNP ,_, including_VBG the_DT
restricted_VBN device_NN authority_NN in_IN section_NN 520_CD (_( e_SYM )_) of_IN the_DT Act_NNP ._. 21_CD U_NNP ._. S_NNP ._. C_NNP ._.
ยง_NN 360_CD j_NN (_( e_SYM )_) ._.
Executive_NNP Order_NNP No_UH ._. 12866_CD
The_DT rule_NN was_VBD determined_VBN to_TO be_VB a_DT "_'' significant_JJ regulatory_JJ action_NN "_''
under_IN Executive_NNP Order_NNP No_UH ._. 12866_CD requiring_VBG review_NN by_IN the_DT Office_NNP of_IN
Management_NNP and_CC Budget_NNP ,_, Office_NNP of_IN Information_NNP and_CC Regulatory_NNP Affairs_NNPS
(_( OIRA_NNP )_) ._. OIRA_NNP approved_VBD the_DT final_JJ rule_NN on_IN August_NNP 22_CD ,_, 1996_CD ,_, as_IN
complying_VBG with_IN the_DT requirements_NNS of_IN the_DT Order_NNP based_VBN on_IN the_DT
information_NN supplied_VBN by_IN FDA_NNP ,_, including_VBG a_DT planned_VBN regulatory_JJ action_NN
document_NN
Page_NNP 4_CD GAO_NNP /_NN OGC-_NNP 96_CD -_: 38_CD
describing_VBG the_DT reason_NN for_IN the_DT rule_NN and_CC an_DT assessment_NN of_IN the_DT
costs_NNS and_CC budgetary_JJ impact_NN of_IN the_DT rule_NN ._.
Executive_NNP Order_NNP No_UH ._. 12606_CD (_( Family_NNP )_)
FDA_NNP considered_VBD whether_IN the_DT rule_NN would_MD have_VB a_DT significant_JJ impact_NN
on_IN family_NN formation_NN ,_, maintenance_NN and_CC general_JJ well-being_NN as_IN required_VBN
by_IN the_DT Order_NNP and_CC found_VBD that_IN the_DT rule_NN would_MD not_RB have_VB a_DT negative_JJ
impact_NN in_IN these_DT areas_NNS ._. In_IN the_DT preamble_NN to_TO the_DT proposed_VBN rule_NN ,_, it_PRP was_VBD
noted_VBN that_IN the_DT rule_NN would_MD help_VB the_DT significant_JJ majority_NN of_IN families_NNS
that_WDT seek_VBP to_TO discourage_VB their_PRP$ children_NNS from_IN using_VBG cigarettes_NNS and_CC
smokeless_JJ tobacco_NN ._. 60_CD Fed_NNP ._. Reg_NNP ._. 41356_CD ._. FDA_NNP responds_VBZ in_IN the_DT preamble_NN
to_TO the_DT final_JJ rule_NN to_TO several_JJ comments_NNS it_PRP received_VBD and_CC maintains_VBZ its_PRP$
conclusion_NN that_IN the_DT rule_NN does_VBZ not_RB have_VB a_DT negative_JJ impact_NN ._.
Executive_NNP Order_NNP No_UH ._. 12612_CD (_( Federalism_NNP )_)
The_DT rule_NN was_VBD reviewed_VBN by_IN the_DT FDA_NNP under_IN the_DT Order_NNP which_WDT requires_VBZ
Federal_NNP agencies_NNS to_TO examine_VB regulatory_JJ actions_NNS to_TO determine_VB if_IN they_PRP
have_VBP a_DT significant_JJ impact_NN on_IN the_DT States_NNPS ,_, on_IN the_DT relationship_NN
between_IN the_DT States_NNPS and_CC the_DT Federal_NNP government_NN ,_, and_CC on_IN the_DT
distribution_NN of_IN power_NN and_CC responsibilities_NNS among_IN the_DT various_JJ levels_NNS
of_IN government_NN ._. In_IN the_DT preamble_NN to_TO the_DT final_JJ rule_NN ,_, the_DT FDA_NNP addresses_VBZ
the_DT various_JJ issues_NNS raised_VBN by_IN commenters_NNS in_IN this_DT area_NN ,_, including_VBG the_DT
preemption_NN of_IN State_NNP and_CC local_JJ laws_NNS which_WDT are_VBP different_JJ from_IN or_CC in_IN
addition_NN to_TO the_DT requirements_NNS under_IN the_DT final_JJ rule_NN ;_: whether_IN there_EX is_VBZ
an_DT infringement_NN on_IN the_DT States_NNPS '_POS right_NN to_TO regulate_VB tobacco_NN and_CC
businesses_NNS within_IN the_DT State_NNP and_CC protect_VB the_DT health_NN of_IN its_PRP$ citizens_NNS ;_:
the_DT allocation_NN of_IN a_DT State_NNP 's_POS resources_NNS and_CC the_DT rule_NN 's_POS possible_JJ
impact_NN on_IN the_DT States_NNPS '_POS economies_NNS ._. The_DT FDA_NNP concludes_VBZ that_IN the_DT
preemptive_JJ effects_NNS of_IN the_DT final_JJ rule_NN are_VBP consistent_JJ with_IN the_DT
Order_NNP ._.
Executive_NNP Order_NNP No_UH ._. 12630_CD (_( Property_NNP Rights_NNP )_)
The_DT FDA_NNP reviewed_VBD the_DT rule_NN under_IN the_DT Order_NNP and_CC concluded_VBD that_IN the_DT
affect_NN of_IN the_DT final_JJ rule_NN would_MD not_RB constitute_VB a_DT "_'' taking_VBG "_'' of_IN private_JJ
property_NN ._. The_DT preamble_NN to_TO the_DT final_JJ rule_NN discusses_NNS issues_NNS raised_VBN by_IN
various_JJ commenters_NNS in_IN the_DT areas_NNS of_IN the_DT use_NN of_IN self-service_JJ
displays_NNS ,_, vending_VBG machines_NNS ,_, restrictions_NNS on_IN sponsorship_NN of_IN events_NNS
except_IN in_IN the_DT corporate_JJ name_NN and_CC loss_NN of_IN employment_NN and_CC maintains_VBZ
its_PRP$ conclusion_NN that_IN there_EX would_MD be_VB no_DT "_'' taking_VBG "_'' under_IN the_DT Order_NNP ._. The_DT
FDA_NNP 's_POS position_NN is_VBZ that_IN reductions_NNS in_IN personal_JJ property_NN 's_POS value_NN ,_,
even_RB prohibitions_NNS on_IN all_DT economically_RB viable_JJ uses_NNS ,_, and_CC financial_JJ
expenditures_NNS to_TO comply_VB with_IN a_DT regulatory_JJ requirement_NN do_VBP not_RB
necessarily_RB establish_VB a_DT taking_NN ,_, citing_VBG various_JJ court_NN decisions_NNS for_IN
support_NN ._.
The_DT FDA_NNP did_VBD not_RB identify_VB any_DT other_JJ statute_NN or_CC executive_NN order_NN
imposing_VBG procedural_JJ requirements_NNS relevant_JJ to_TO the_DT rule_NN ._.
Page_NNP 5_CD GAO_NNP /_NN OGC-_NNP 96_CD -_: 38_CD



